The international summit on genome editing kicked off on Tuesday at the headquarters of the National Academy of Sciences, Washington, D.C. Several scientists and researchers gathered for the three-day conference that will discuss the scientific, ethical and governance issues associated with human gene-editing technologies.
The summit particularly focuses on whether gene editing of human embryos for therapeutic reasons should be considered or ruled out altogether, The Guardian noted.
“The overriding question is when, if ever, we will want to use gene editing to change human inheritance," summit chair David Baltimore of Caltech said in his introductory remarks. “We are close to altering human heredity and we need to decide how we as a society are going to use this capability.”
According to The Australian, the process fixing defecting genes is very complicated, so much so that it has slowed down the development of genetic therapies. With gene editing technology, scientists use molecular tools to repair or replace a defective gene or delete it.
A new tool called CRISPR-Cas9 has been adopted by laboratories worldwide as it is faster, economical, and simple enough to use with minimal level of training. Scientists hope to use the tool for diseases like sickle cell, fixing the defective gene in someone's own blood-producing cells instead of implanting donated ones.
Jennifer Doudna of the University of California at Berkeley is one of the pioneers of the CRISPR technology. Doudna told reporters that it will still take several years before the tool can be used for treatment of human diseases, The Washington Post reported.
"We don't understand enough yet about the human genome, and how genes interact, and which genes give rise to certain traits to edit for human enhancement today," she said.
Marcy Darnovsky of the Center for Genetics and Society advocacy group, however, opposes heritable gene editing and calls it potentially a "society-altering technology."


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Google Halts UK YouTube TV Measurement Service After Legal Action
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 



